Back to Search Start Over

REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.

Authors :
Bommier, C.
Donzel, M.
Rossi, C.
Fornecker, L.
Bijou, F.
Chauchet, A.
Lebras, L.
Ysebaert, L.
Haioun, C.
Bouabdallah, K.
Morineau, N.
Gastinne, T.
Amorim, S.
Jardin, F.
Abraham, J.
Lamy de la Chapelle, T.
Gressin, R.
Fouillet, L.
Fruchart, C.
Morschhauser, F.
Source :
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p387-388, 2p
Publication Year :
2023

Abstract

Regarding the B initial workup b , while at least one imagery was offered in 97% of patients, SP 18 sp FDG-PET/CT (EMZL 78%, SMZL 62%, NMZL 78%) was performed more frequently than CT-scan at baseline (EMZL 73%, SMZL 62%, NMZL 71%), although 47% patients underwent both procedures. Diagnosis of MZL was mostly evoked by general practitioners (48%) but patients were finally treated by hematologists (98%). B Background: b Marginal Zone Lymphomas (MZL) are a heterogeneous group of lymphomas that include three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). [Extracted from the article]

Subjects

Subjects :
LYMPHOMAS
NON-Hodgkin's lymphoma

Details

Language :
English
ISSN :
02780232
Volume :
41
Database :
Complementary Index
Journal :
Hematological Oncology
Publication Type :
Academic Journal
Accession number :
164231083
Full Text :
https://doi.org/10.1002/hon.3164_281